A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.

BACKGROUND Treatment with angiotensin-converting-enzyme (ACE) inhibitors reduces mortality among survivors of acute myocardial infarction, but whether to use ACE inhibitors in all patients or only in selected patients is uncertain. METHODS We screened 6676 consecutive patients with 7001 myocardial infarctions confirmed by enzyme studies. A total of 2606 patients had echocardiographic evidence of left ventricular systolic dysfunction (ejection fraction, < or = 35 percent). On days 3 to 7 after infarction, 1749 patients were randomly assigned to receive oral trandolapril (876 patients) or placebo (873 patients). The duration of follow-up was 24 to 50 months. RESULTS During the study period, 304 patients (34.7 percent) in the trandolapril group died, as compared with 369 (42.3 percent) in the placebo group (P = 0.001). The relative risk of death in the trandolapril group, as compared with the placebo group, was 0.78 (95 percent confidence interval, 0.67 to 0.91). Trandolapril also reduced the risk of death from cardiovascular causes (relative risk, 0.75; 95 percent confidence interval, 0.63 to 0.89; P = 0.001) and sudden death (relative risk, 0.76; 95 percent confidence interval, 0.59 to 0.98; P = 0.03). Progression to severe heart failure was less frequent in the trandolapril group (relative risk, 0.71; 95 percent confidence interval, 0.56 to 0.89; P = 0.003). In contrast, the risk of recurrent myocardial infarction (fatal or nonfatal) was not significantly reduced (relative risk, 0.86; 95 percent confidence interval, 0.66 to 1.13; P = 0.29). CONCLUSIONS Long-term treatment with trandolapril in patients with reduced left ventricular function soon after myocardial infarction significantly reduced the risk of overall mortality, mortality from cardiovascular causes, sudden death, and the development of severe heart failure. That mortality was reduced in a randomized study enrolling 25 percent of consecutive patients screened should encourage the selective use of ACE inhibition after myocardial infarction.

[1]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[2]  Raymond C. Schneider,et al.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.

[3]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[4]  L. Køber,et al.  An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies (as used in the TRACE study). TRAndolapril Cardiac Evaluation. , 1994, European heart journal.

[5]  J. Berning,et al.  Early estimation of risk by echocardiographic determination of wall motion index in an unselected population with acute myocardial infarction. , 1990, The American journal of cardiology.

[6]  L. Køber,et al.  Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) study. , 1995, The American journal of cardiology.

[7]  L. Opie,et al.  Chronic oral pretreatment with the angiotensin converting enzyme inhibitor, trandolapril decreases ventricular fibrillation in acute ischaemia and reperfusion. , 1994, European heart journal.

[8]  S. Ball,et al.  Angiotensin-converting enzyme inhibitors after myocardial infarction: indications and timing. , 1995, Journal of the American College of Cardiology.

[9]  W. G. Cochran.  Some Methods for Strengthening the Common χ 2 Tests , 1954 .

[10]  B. Magnani,et al.  The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction , 1995 .

[11]  A. Weyman,et al.  Cross-sectional Echocardiographic Analysis of the Extent of Left Ventricular Asynergy in Acute Myocardial Infarction , 1980, Circulation.

[12]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  GISSI-3: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction , 1994, The Lancet.

[13]  R. Temple,et al.  More on the survival and ventricular enlargement trial. , 1993, The New England journal of medicine.

[14]  G. Murray,et al.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .

[15]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[16]  K. Swedberg,et al.  Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) , 1992, The New England journal of medicine.

[17]  A. Timmis,et al.  Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis. , 1993, BMJ.

[18]  J. Herlitz,et al.  Characteristics and prognosis of patients with acute myocardial infarction in relation to occurrence of congestive heart failure. , 1994, European heart journal.

[19]  P. Andersen,et al.  Rapid estimation of left ventricular ejection fraction in acute myocardial infarction by echocardiographic wall motion analysis. , 1992, Cardiology.

[20]  E. Prystowsky,et al.  Physiological Substrate for Antidromic Reciprocating Tachycardia: Prerequisite Characteristics of the Accessory Pathway and Atrioventricular Conduction System , 1992, Circulation.